Diagnostic Approach for Rheumatoid Arthritis with Positive RF and Negative ANA

Clinical Context and Differential Diagnosis

The American College of Rheumatology suggests that a positive rheumatoid factor with negative ANA most strongly suggests rheumatoid arthritis, with a recommendation to order anti-CCP antibodies, inflammatory markers, complete blood count, comprehensive metabolic panel, and bilateral hand/wrist/foot X-rays while arranging urgent rheumatology referral within 6 weeks 1, 2
Rheumatoid arthritis is the most likely diagnosis, as RF positivity occurs in 60-80% of RA patients, and negative ANA helps exclude systemic lupus erythematosus 1, 3
The negative ANA effectively excludes SLE as a primary diagnosis, since the American College of Rheumatology requires at least 1:80 ANA titer to even begin considering SLE 3
Sjögren's syndrome remains possible despite negative ANA, as some patients present with RF positivity and negative anti-Ro/La antibodies 4, 5

The American College of Rheumatology recommends ordering anti-CCP antibodies, as anti-CCP has superior specificity compared to RF and will confirm RA diagnosis in RF-positive patients 1, 2
Both ESR and CRP should be obtained at baseline, with CRP preferred for ongoing monitoring as it's more reliable and not age-dependent 2, 6
A complete blood count with differential is essential to assess for cytopenias before starting treatment and to calculate disease activity measures 2
A comprehensive metabolic panel, including liver function tests, renal function, glucose, and urate levels, is necessary for baseline assessment and monitoring 2

Bilateral hand, wrist, and foot X-rays should be obtained immediately, as the presence of erosions on baseline radiographs is highly predictive for RA diagnosis and disease persistence 2

The American College of Rheumatology and European League Against Rheumatism suggest calculating the diagnostic score using an algorithm, where ≥6/10 points = definite RA, with joint involvement, serology, acute phase reactants, and duration of symptoms considered 1, 2
Joint involvement scoring ranges from 0 to 5 points, depending on the number of large and small joints involved 2
Serology scoring ranges from 0 to 3 points, depending on RF and ACPA status 1, 2

The American College of Rheumatology recommends starting methotrexate 15 mg weekly immediately after confirming clinical synovitis, with a plan to escalate to 20-25 mg weekly based on response 2, 3
Concurrent therapy includes folic acid 1 mg daily to reduce methotrexate toxicity, and prednisone 10-20 mg daily as bridge therapy for 4-8 weeks, then taper 2, 3
The treatment target is remission (SDAI ≤3.3) or low disease activity (SDAI ≤11) 2, 3

Disease activity should be reassessed every 4-6 weeks using SDAI with 28-joint count, with CRP and ESR repeated at each visit to monitor inflammatory activity 2, 3
Hand, wrist, and foot X-rays should be repeated at 6 months and 12 months to assess radiographic progression 2, 3
CBC, liver function, and renal function should be monitored regularly during methotrexate therapy 2, 3